Cumberland Pharmaceuticals CPIX Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 85%+2.4pp | 82.6%-2.1pp | 84.7%+6.4pp | 78.3%+2.8pp | |
| Operating margin | -6.3%+10.7pp | -17%+7.2pp | -24.2%-10.6pp | -13.6%+7.8pp | |
| Net margin | -6.4%+10.7pp | -17.1%-1.2pp | -15.9%-2.6pp | -13.3%-3.5pp | |
| Returns | |||||
| Return on equity | -11.9%+12.8pp | -24.7%-5.6pp | -19.1%-5.0pp | -14.1%-6.3pp | |
| Return on invested capital | -16.6%+23.3pp | -39.9%+10.1pp | -50%-20.1pp | -29.9%+7.4pp | |
| Efficiency | |||||
| Asset turnover | 0.6×+0.1× | 0.5×0.0× | 0.5×0.0× | 0.5×+0.1× | |
| Liquidity | |||||
| Current ratio | 1×-0.1× | 1.2×-0.1× | 1.3×-0.3× | 1.6×-0.8× | |
| Leverage | |||||
| Debt-to-equity | 0.2×-0.3× | 0.5×+0.3× | 0.2×+0.1× | 0.1×+0.1× | |
| Net debt / EBITDA | -4.8×— | —— | —— | —— | |
| Per Share | |||||
| Book value per share | $1.67+3.0% | $1.63-21.5% | $2.07-16.9% | $2.49-13.3% | |
| Valuation | |||||
| Market capitalization | $97.09M+142% | $33.28M+31.3% | $25.35M-21.8% | $32.4M-52.8% | |
| Price / sales | 2.3×+1.4× | 0.9×+0.2× | 0.6×-0.1× | 0.8×-1.1× | |
| Price / book | 4.5×+3.1× | 1.5×+0.6× | 0.9×0.0× | 0.9×-0.7× | |
| EV / EBITDA | 39.2×— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Cumberland Pharmaceuticals's profit margins?
- Cumberland Pharmaceuticals (CPIX) runs a 82.9% gross margin and a -17.2% operating margin, with a -17.6% net margin.
- Where do Cumberland Pharmaceuticals's ratios come from?
- Every ratio is computed from Cumberland Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
